| FRIDAY, APRIL 4, 2025 | ||
 | ||
| SANTEN INDUSTRY SPONSORED LUNCHEON SYMPOSIUM | ||
| 12:15–13:15 | How can patient-focused glaucoma management provide individualised treatment beyond IOP control? (Lunch boxes served 12:00–12:15) | HALL A |
| Moderator: | Francesca Cordeiro, UK | |
| Speakers: | Ernst R. Tamm, Germany; José Belda, Spain; Francesco Oddone, Italy | |
| 12:15-12:20 | ||
| 12:20-12:40 | Can underlying structure be used for strategies to provide individualised treatment for IOP control and beyond? Ernst R. Tamm, Germany With debate and panel discussion | |
| 12:40-12:55 | Can monotherapies deliver additional benefits for individualised treatment beyond IOP control? José Belda, Spain With debate and panel discussion | |
| 12:55-13:10 | Can understanding what’s behind IOP control shape expectations for individualised treatment? Francesco Oddone, Italy With debate and panel discussion | |
| 13:10-13:15 | Summary and close Francesca Cordeiro, UK | |
| This event is organised and funded by Santen and will contain information on Santen products. | ||
 | ||
| ABBVIE INDUSTRY SPONSORED DESSERT SYMPOSIUM | ||
| 13:30-14:30 | Patient-centric elevation of standard of care in DME and RVO: 3 discussions (Dessert boxes served 13:15-13:30) | HALL A |
| 13:30-13:36 | Welcome and introduction Anat Loewenstein, Israel | |
| 13:36-13:53 13:36-13:41 13:41-13:46 13:46-13:53 | From pathophysiology to clinical practice: Is what you see what you get? Francine Behar-Cohen, France Laurent Kodjikian, France Discussion and Q&A (facilitated by Anat Loewenstein) | |
| 13:53-14:10 13:53-13:58 13:58-14:03 14:03-14:10 | Should corticosteroids be considered as first-line therapy for DME and RVO? For 1L: Patricia Udaondo, Spain For 2L: Fang Lu, China Discussion and Q&A (facilitated by Anat Loewenstein & Laurent Kodjikian) | |
| 14:10-14:27 14:10-14:15 14:15-14:20 14:20-14:27 | Clinicians should wait until fluid recurrence before re-treating patients with DME or RVO Thibaud Mathis, France Anat Loewenstein, Israel Discussion and Q&A (facilitated by Laurent Kodjikian) | |
| 14:27-14:30 | Close and meeting adjournment Anat Loewenstein, Israel | |
 | ||
| OCULAR INDUSTRY SPONSORED SYMPOSIUM | ||
| 17:30-18:30 | Advancing retinal disease treatment: Extending durability with OTX-TKI | HALL A |
| Moderator: | ||
| Faculty: | Lloyd Clark, USA and Daniel Martin, USA | |
| SATURDAY, APRIL 5, 2025 | ||
| “On the Horizon” Industries Sponsored Breakfast Symposium | ||
| 07:30-08:30 | Industry leaders presenting what is new in the piepline, emerging technologies and drugs (Light breakfast will be served from 07:00-07:30 at the entrance of the hall) | HALL A |
| Moderators: | Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
| Oculis – rethinking ophthalmology Riad Sherif, Switzerland |  | |
| The Leader in Sustained Release Drug Delivery Presenter Courtney Goodwin, USA |  | |
| Novel modifier gene therapy for the treatment of retinitis pigmentosa, Stargardt disease, and geographic atrophy Huma Qamar, USA |  | |
| Committed to preserving vision in those affected by retinal diseases Lloyd Clark, USA |  | |
 | ||
| BAYER INDUSTRY SPONSORED LUNCHEON SYMPOSIUM | ||
| 12:15-13:15 | Controversies in ophthalmology: spotlight on next generation patient care (Lunch boxes served 12:00-12:15) | HALL A |
| Chair: | Anat Loewenstein, Israel | |
| 12:15-12:17 | Welcome and introductions Anat Loewenstein, Israel | |
| 12:17-12:22 | Our vision in ophthalmology: the latest with aflibercept 8mg Anat Loewenstein, Israel | |
| 12:22-12:37 | Does aflibercept 8mg provide better drying where it matters? Paolo Lanzetta, Italy | |
| 12:37-12:52 | Why is aflibercept 8mg a clear choice for treatment-naïve patients? David Brown, USA | |
| 12:52-13:02 | How can aflibercept 8mg shape your future practice? Patricia Udaondo, Spain | |
| 13:02-13:12 | Aflibercept 8mg in the clinic: expert perspectives Moderator: Anat Loewenstein, Israel Panel: All Speakers | |
| 13:12-13:15 | Summary and close Anat Loewenstein, Israel | |
| “On the Horizon” Industries Sponsored Dessert Symposium | ||
| 13:30-14:30 | Industry leaders presenting advances in gene therpay (Dessert boxes served 13:15-13:30) | HALL A |
| Moderators: | Anat Loewenstein, Israel; Baruch Kuppermann, USA | |
| 13:30-13:40 | Welcome and Overview Baruch Kuppermann, USA | |
| 13:40-14:00 | 4D-150: An investigational intravitreal gene therapy to reduce treatment burden in nAMD and DME Melissa A. Calton, USA Baruch Kuppermann USA |  |
| 14:00-14:20 | Ixoberogene Soroparvovec (Ixo-vec) intravitreal gene therapy for neovascular AMD Stela Vujosevic, Italy Paolo Lanzetta, Italy |  |
| 14:20-14:30 | Discussion |